Valsartan 320 mg: Uses, Dosage, and Side Effects

Valsartan 320 mg is the highest standard dose of a widely prescribed blood pressure medication, used primarily to treat hypertension, heart failure, and to protect the heart after a heart attack. It belongs to a class of drugs called angiotensin receptor blockers (ARBs), and the 320 mg tablet represents the ceiling dose for most adults with high blood pressure. What makes the dosing picture interesting is that the jump from lower doses to 320 mg does not always produce dramatic additional blood pressure lowering, yet the higher dose plays a distinct role in heart failure and kidney protection that goes beyond what the numbers on a blood pressure cuff might suggest.

How Valsartan Works

Your body naturally produces a hormone called angiotensin II, which tightens blood vessels and drives up blood pressure. Valsartan blocks the receptor where angiotensin II latches on, specifically the AT1 receptor subtype responsible for most of that hormone’s cardiovascular effects.¹ By sitting in that receptor’s binding site, valsartan prevents angiotensin II from constricting arteries, promoting sodium retention, and triggering the cascade of signals that remodel heart and kidney tissue over time. The selectivity matters: valsartan targets AT1 specifically and does not interfere with the AT2 receptor, which may have some protective functions of its own.²

Blood Pressure Lowering at 320 mg

Valsartan is available in several strengths, typically starting at 80 mg or 160 mg for hypertension. Clinical trials show a clear dose-response pattern: higher doses produce greater drops in both systolic and diastolic blood pressure. Starting at 160 mg delivers larger reductions and gets a higher proportion of patients to their target than 80 mg.³ That said, the incremental blood pressure benefit flattens out somewhat above 80 mg. All doses produce statistically meaningful reductions compared to a sugar pill, but the extra millimeters of mercury you gain moving from 160 mg to 320 mg tend to be modest.⁴

This matters practically. If you are already on 160 mg and your blood pressure is only slightly above goal, your doctor might bump you to 320 mg. But if you need a much bigger drop, the more effective move is often adding a second medication rather than simply doubling the valsartan dose. The combination of valsartan 320 mg with hydrochlorothiazide, a diuretic, brings roughly 70 to 75 percent of patients to goal, compared with about 53 percent on valsartan 320 mg alone.⁵

Heart Failure and Post-Heart Attack Use

Lowering blood pressure is only part of the story. Valsartan at higher doses plays a major role in managing heart failure with reduced pumping ability. In a large randomized trial, valsartan reduced the combined risk of death and heart failure hospitalization by about 13 percent compared with placebo, driven mainly by fewer hospitalizations for worsening heart failure.⁶ Separate long-term data found that patients on valsartan monotherapy had substantially lower rates of developing heart failure compared to those on a different blood pressure drug, and the benefit grew the longer patients stayed on therapy.⁷

After a heart attack complicated by heart failure or weakened pumping function, valsartan performs on par with captopril, a well-established ACE inhibitor that was long considered the standard of care. A large trial comparing the two found essentially identical mortality rates over roughly two years of follow-up, meeting the statistical bar for noninferiority.⁸ Combining valsartan and captopril together offered no additional survival benefit over either drug alone but did increase side effects, so the combination is not recommended.⁹ This gave clinicians a practical alternative for post-heart attack patients who could not tolerate an ACE inhibitor.

Common Side Effects

Valsartan at any dose, including 320 mg, is generally well tolerated. The most frequently reported side effects are fatigue, dizziness, headache, and nausea, but in clinical trials these occurred at rates similar to placebo, meaning many people experience them regardless of whether they are actually taking the drug.¹⁰ Among post-heart attack patients, the rate of people stopping the drug because of side effects was actually lower with valsartan than with ACE inhibitors, where persistent cough is a common nuisance.

That cough difference deserves emphasis because it is one of the main reasons people are switched from an ACE inhibitor to an ARB like valsartan. A head-to-head trial found that persistent dry cough occurred in about 19 percent of valsartan users versus roughly 69 percent of those on lisinopril, a commonly prescribed ACE inhibitor. The cough rate with valsartan was no different from that of a diuretic placebo comparator.¹¹ If you switched to valsartan because of ACE inhibitor cough, the 320 mg dose should not reintroduce that problem.

Potassium and Kidney Monitoring

The side effect that requires the most real-world vigilance is elevated potassium. Because valsartan blocks the hormonal pathway that normally tells your kidneys to excrete potassium, levels can creep up, especially if kidney function is already impaired. This risk is amplified in newer combination products like sacubitril/valsartan, where one heart failure center found that elevated potassium above 5.0 mmol/L developed in over 40 percent of patients within three months of starting the combination, though severe elevations requiring drug discontinuation were uncommon.¹² Plain valsartan carries the same directional risk, though typically at lower rates. Your doctor will check your blood potassium and kidney function via a simple blood draw, usually within a few weeks of starting or increasing the dose.

On the kidney-protection side, valsartan shows promise that extends beyond blood pressure control. In people with type 2 diabetes and early kidney damage, even low doses of valsartan reduced protein leaking into the urine, a key marker of kidney deterioration, and the benefit appeared at doses too low to change blood pressure at all.¹³ In people with non-diabetic kidney disease, valsartan slowed the rate at which kidney function declined compared with placebo.¹⁴ Animal research has even shown that higher valsartan doses keep reducing protein in the urine in a dose-dependent fashion, even after blood pressure has plateaued.¹⁵ This is part of why some clinicians push the dose to 320 mg in patients with kidney concerns: the organ-protective effects may continue climbing even when the blood pressure benefit has leveled off.

Morning or Bedtime Dosing

One practical question that often goes unaddressed is when to take valsartan. It turns out the answer depends partly on your blood pressure pattern overnight. Normally, blood pressure dips during sleep. In people whose pressure fails to dip (called “non-dippers”), cardiovascular risk is higher. A study using 24-hour blood pressure monitoring found that valsartan taken at bedtime produced significantly greater nighttime blood pressure reductions than the same dose taken in the morning, with about 76 percent of non-dippers reverting to a normal dipping pattern after three months of bedtime dosing.¹⁶ A separate ambulatory monitoring study confirmed a roughly 6 percent improvement in the day-to-night blood pressure ratio with bedtime dosing, translating to a 73 percent relative reduction in non-dipper status.¹⁷

Both studies also confirmed that valsartan controls daytime blood pressure effectively regardless of when you take it. So if you take it in the morning and your pressure is well controlled throughout the day and night, there is no reason to switch. But if your doctor sees a non-dipping pattern on ambulatory monitoring, moving the dose to bedtime is a straightforward way to address it.

Drug Interactions Worth Knowing

Valsartan’s biggest interaction risk comes from combinations that pile up on the kidneys or push potassium higher. The combination of a drug in valsartan’s class with a diuretic and an NSAID pain reliever (ibuprofen, naproxen, and similar) is sometimes called the “triple whammy” because it raises the risk of acute kidney injury.¹⁸ Taking an occasional over-the-counter NSAID while on valsartan and a diuretic probably will not cause disaster in someone with healthy kidneys, but routine daily use of NSAIDs alongside valsartan warrants a conversation with your prescriber.

On the potassium front, a broad review identified several classes of medications that can amplify the risk of high potassium when taken alongside any RAAS blocker like valsartan. These include potassium-sparing diuretics (such as spironolactone), potassium supplements, the antibiotic trimethoprim, certain antifungal agents, beta-blockers, and NSAIDs themselves.¹⁹ None of these are absolute prohibitions; many heart failure patients safely take valsartan and spironolactone together under close lab monitoring. The key is that your care team needs to know everything you take so they can adjust doses and check blood work at the right intervals.

Who Should Not Take Valsartan

The most critical contraindication is pregnancy. Drugs that block the renin-angiotensin system, including valsartan, can cause severe harm to a developing fetus, particularly in the second and third trimesters. A systematic review documented neonatal complications including kidney failure, dangerously low amniotic fluid, respiratory failure, abnormal skull development, and death.²⁰ Even late-pregnancy exposure can cause severe fetal kidney impairment, though case reports suggest some reversibility if the drug is stopped promptly.²¹ If you are planning a pregnancy or discover you are pregnant while taking valsartan, stopping the drug and contacting your provider immediately is essential. Pediatric hypertension guidelines similarly flag the need for caution in sexually active adolescent females for this reason.²²

People with severe liver disease also need attention. Valsartan is cleared mainly through the liver and excreted in the stool, with very little metabolism. Pharmacokinetic studies show that patients with even mild-to-moderate liver impairment have about double the drug exposure compared with healthy people matched for age and weight.²³ That does not automatically rule out using it, but it means lower starting doses and closer monitoring are warranted.

What Happens in Your Body After a Dose

Once you swallow a 320 mg tablet, valsartan reaches peak blood levels within about one to two hours.²⁴ It has a half-life of roughly seven to eight hours, meaning the body clears about half of it in that timeframe. The drug is barely metabolized and most of it leaves the body unchanged in the stool.²⁵

One quirk of valsartan is that tablets deliver a smaller fraction of the dose into the bloodstream than liquid formulations. Studies show that liquid forms roughly double the peak blood concentration and increase overall absorption by 50 to 75 percent compared with tablets.²⁶ This rarely matters in daily practice because doses were developed and tested in tablet form, so the approved doses already account for the tablet’s lower absorption. But it does matter if a pharmacist needs to prepare a liquid suspension for someone who cannot swallow pills, because the dose may need adjustment.

Single-Pill Combinations and Sticking With Treatment

One of the bigger real-world challenges with blood pressure medication is that people stop taking it. Combining valsartan with another drug in a single pill seems to help. A study comparing single-pill valsartan/amlodipine with the same two drugs taken as separate pills found that patients on the single pill were significantly more likely to stay on treatment and had total healthcare costs roughly 16 to 20 percent lower.²⁷ A triple-combination pill of amlodipine, valsartan, and hydrochlorothiazide showed even more striking adherence advantages: persistence rates were about double those of the same three drugs taken as separate pills, and emergency room visits were notably less frequent in the single-pill group.²⁸ If you find yourself on multiple blood pressure medications, asking your doctor whether a combination pill exists can simplify your routine and reduce the odds of accidentally skipping doses.

The 2018 Nitrosamine Recall

In mid-2018, regulators worldwide recalled certain valsartan products after discovering that some batches contained nitrosamine impurities, specifically NDMA and NDEA, which are classified as probable carcinogens.²⁹ The contamination traced back to changes in the manufacturing process for the active ingredient at certain overseas suppliers, where the potential for generating these impurities had not been adequately assessed. The recall affected generic valsartan products from specific manufacturers, not the entire global supply. Following the recall, the number of patients exposed, the duration of their exposure, and any actual cancer risk remained uncertain.³⁰

If you are currently taking valsartan, the products on pharmacy shelves today have been manufactured under much stricter testing requirements for nitrosamine impurities. The recall was a manufacturing quality failure, not a problem inherent to the molecule itself. Regulators now enforce tight limits on nitrosamine levels in all ARB products.

Valsartan in Children

Valsartan is one of the few blood pressure drugs with solid clinical trial data in children, including very young ones. In children aged one to five years with hypertension, a higher weight-based dose of valsartan (4 mg per kilogram) produced greater blood pressure reductions than a low dose, confirming a dose-response relationship even in small children. Side effects were actually less common in the higher-dose group.³¹ A separate trial in the same age group showed that nearly 77 percent of children achieved blood pressure below the 95th percentile during open-label treatment, with no measurable negative effects on growth and development.³² These were among the first antihypertensive trials ever conducted in children under six, and they established valsartan as a viable option in pediatric care. Pediatric doses are calculated by body weight, so the 320 mg adult tablet is not appropriate for children; a pharmacist can compound appropriate liquid doses when needed.